Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
MAMC was established in 1958 and is located in
"Cases of COVID-19 infection that require hospitalization continue to occur in
Aethlon Medical's clinical trial of the Hemopurifier in patients with SARS-CoV-2, or COVID-19, in the ICU with severe or life-threatening disease, is designed to enroll up to 15 patients at up to three centers throughout
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.
The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to enroll patients in its clinical trials in
Chief Financial Officer
Aethlon Medical, Inc.
S.A. Noonan Communications, LLC
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-receives-ethics-board-approval-to-add-second-site-to-its-ongoing-clinical-trial-of-its-hemopurifier-to-treat-severe-covid-19-in-india-301830177.html
SOURCE Aethlon Medical, Inc.